CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against Moderna

German biotech company CureVac has filed a lawsuit against its American rival Moderna, alleging patent infringement related to COVID-19 vaccines. CureVac claims that Moderna's mRNA-based vaccines violate its patents and is seeking compensation. The lawsuit was filed in a regional court in Düsseldorf, Germany. CureVac asserts that Moderna's Spikevax vaccine uses mRNA technology that CureVac developed in the early 2010s. The company argues that this technology existed before the COVID-19 pandemic and that its patents remain valid. Moderna denies the allegations, stating that its technology was developed independently. The company contends that CureVac's patents are either invalid or not applicable. Moderna has faced similar patent disputes in the past. This case has reignited debates over intellectual property rights related to COVID-19 vaccines. Experts note that such lawsuits could impact vaccine development and distribution. However, the outcome may take time, and both parties might seek a settlement. This is not investment advice.